))
OS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next Steps
Manage episode 466376119 series 3645695
Content provided by Joe Brunetto. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Joe Brunetto or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
CEO Paul Romness and CBO Gerald Commisiong of OS Therapies join us on our WTR Biotech Spotlight podcast to talk about the OST-HER2 Phase 2b data in recurrent, liver metastatic osteosarcoma and what it could mean for patients with this aggressive cancer. We discuss the plan to approach the FDA and their confidence in a potential accelerated filing. Listen to learn more about OS Therapies and its cancer immunotherapy.
9 episodes
Share
